Abstract
Purpose
Placental growth factor (PlGF) is a member of the VEGF family that plays an important role in experimental models of diabetic retinopathy and retinal neovascularization. We aimed to investigate whether vitreous levels of PlGF correlated with proliferative diabetic retinopathy (PDR) status, VEGF levels, and bevacizumab treatment. We also analysed PDR membranes to confirm the presence of the PlGF receptor, FLT1, in endothelial cells.
Methods
This was a case-control study: undiluted vitreous fluid samples were obtained from 28 active PDR patients without preoperative bevacizumab treatment, 21 active PDR patients with preoperative bevacizumab treatment, 18 inactive PDR patients, and 21 control patients. PlGF and VEGF levels in samples were determined by enzyme-linked immunosorbent assay. Immunohistochemistry for FLT1 was performed on human PDR membranes.
Results
Compared to control, vitreous PlGF levels were higher in both active PDR without bevacizumab (P<0.0001) and with bevacizumab (P<0.0001). There was no significant difference in PlGF between active PDR patients without and with bevacizumab (P=0.56). Compared to active PDR, PlGF levels were significantly reduced in inactive PDR (P=0.004). PlGF levels were highly correlated with VEGF levels in active PDR. VEGFR1 was expressed in endothelial cells in human PDR membranes.
Conclusion
The strong correlation of PlGF levels with PDR disease status and expression of FLT1 in human PDR membranes suggest that PlGF has a pathogenic role in proliferative diabetic retinopathy. Therapeutic targeting of PlGF with agents like aflibercept may be beneficial.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Cheung N, Mitchell P, Wong TY . Diabetic retinopathy. Lancet 2010; 376 (9735): 124–136.
Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ et al. Diabetes mellitus in Saudi Arabia. Saudi Med J 2004; 25 (11): 1603–1610.
Al-Rubeaan K, Abu El-Asrar AM, Youssef AM, Subhani SN, Ahmad NA, Al-Sharqawi AH et al. Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. Acta Ophthalmol 2015; 93 (2): e140–e147.
El-Asrar AM, Al-Rubeaan KA, Al-Amro SA, Kangave D, Moharram OA . Risk factors for diabetic retinopathy among Saudi diabetics. Int Ophthalmol 1998; 22 (3): 155–161.
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35 (3): 556–564.
Aiello LP . Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005; 353 (8): 839–841.
Dewerchin M, Carmeliet P . Placental growth factor in cancer. Expert Opin Ther Targets 2014; 18 (11): 1339–1354.
De Falco S . The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012; 44 (1): 1–9.
Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7 (5): 575–583.
Huang H, He J, Johnson D, Wei Y, Liu Y, Wang S et al. Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1alpha-VEGF pathway inhibition. Diabetes 2015; 64 (1): 200–212.
Osaadon P, Fagan XJ, Lifshitz T, Levy J . A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye 2014; 28 (5): 510–520.
Stewart MW . Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol 2014; 7 (2): 167–180.
Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 2009; 116 (5): 921–926.
Suzuki Y, Suzuki K, Yokoi Y, Miyagawa Y, Metoki T, Nakazawa M . Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy. Retina 2014; 34 (1): 165–171.
Zhao B, Cai J, Boulton M . Expression of placenta growth factor is regulated by both VEGF and hyperglycaemia via VEGFR-2. Microvasc Res 2004; 68 (3): 239–246.
Yao YG, Yang HS, Cao Z, Danielsson J, Duh EJ . Upregulation of placental growth factor by vascular endothelial growth factor via a post-transcriptional mechanism. FEBS Lett 2005; 579 (5): 1227–1234.
Khaliq A, Foreman D, Ahmed A, Weich H, Gregor Z, McLeod D et al. Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest 1998; 78 (1): 109–116.
Mitamura Y, Tashimo A, Nakamura Y, Tagawa H, Ohtsuka K, Mizue Y et al. Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care 2002; 25 (12): 2352.
Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014; 121 (1): 150–161.
Bakri SJ, Moshfeghi DM, Francom S, Rundle AC, Reshef DS, Lee PP et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology 2014; 121 (5): 1102–1108.
Kovacs K, Marra KV, Yu G, Wagley S, Ma J, Teague GC et al. Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia. Invest Ophthalmol Vis Sci 2015; 56 (11): 6523–6530.
Campochiaro PA . Ocular neovascularization. J Mol Med 2013; 91 (3): 311–321.
Loges S, Schmidt T, Carmeliet P . ‘Antimyeloangiogenic’ therapy for cancer by inhibiting PlGF. Clin Cancer Res 2009; 15 (11): 3648–3653.
Diabetic Retinopathy Clinical Research N, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372 (13): 1193–1203.
Stewart MW, Grippon S, Kirkpatrick P . Aflibercept. Nat Rev Drug Discov 2012; 11 (4): 269–270.
Moradi A, Sepah YJ, Sadiq MA, Nasir H, Kherani S, Sophie R et al. Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes 2013; 4 (6): 303–309.
Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9 (7): 936–943.
Acknowledgements
This work was supported by a KKESH/JHU-WEI grant and a Research to Prevent Blindness Career Development Award (EJD). We thank Iftikhar Ahmed and Ches Souru (Department of Research, King Khaled Eye Specialist Hospital, Riyadh, KSA) for coordinating collection of specimens and patient information.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Al Kahtani, E., Xu, Z., Al Rashaed, S. et al. Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment. Eye 31, 529–536 (2017). https://doi.org/10.1038/eye.2016.246
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2016.246
This article is cited by
-
Plasma multi-omics and machine learning reveal predictive biomarkers for type 2 diabetes and retinopathy in Qatar biobank cohort
Journal of Translational Medicine (2025)
-
Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product
Ophthalmology and Therapy (2025)
-
Analytical and Functional Similarity of Aflibercept Biosimilar ABPÂ 938 with Aflibercept Reference Product
Ophthalmology and Therapy (2024)
-
Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial
Eye (2024)
-
Vitreous humor proteome: unraveling the molecular mechanisms underlying proliferative and neovascular vitreoretinal diseases
Cellular and Molecular Life Sciences (2023)
